Cannabis for Cognitive Impairment
Trial Summary
What is the purpose of this trial?
The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any medications that could affect the study outcomes.
What data supports the effectiveness of the drug Cannabis for Cognitive Impairment?
Is cannabis safe for human use?
Cannabis, particularly its component THC, can cause short-term effects like feeling 'high', cognitive issues, and irritability. CBD, another component, is generally considered to have a favorable safety profile and is being studied for various medical uses. However, more research is needed to fully understand the long-term safety of cannabis and its components.23678
How does the drug Cannabis differ from other treatments for cognitive impairment?
Cannabis, particularly its components THC and CBD, is unique because it may offer cognitive benefits by potentially reducing inflammation and improving memory, unlike other treatments that do not target these specific mechanisms. Additionally, CBD is noted for its non-intoxicating properties and potential to counteract the cognitive impairments often associated with THC, making the combination of these cannabinoids a novel approach for cognitive impairment.235910
Research Team
Dustin C Lee, PhD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for frequent and infrequent cannabis users to study how THC affects eye movements and attention. Participants must be able to consume THC and perform tasks that test their oculomotor function and sustained attention.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive varying doses of THC (0 mg, 5 mg, 30 mg) to assess oculomotor and cognitive performance
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cannabis
Cannabis is already approved in Canada, United States, European Union for the following indications:
- Chronic pain
- Nausea and vomiting associated with chemotherapy
- Spasticity associated with multiple sclerosis
- Seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
- Nausea and vomiting associated with chemotherapy
- Spasticity associated with multiple sclerosis
- Chronic pain
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator